Though lung cancer looks promising a partner is now needed.

With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.

The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.

A more comprehensive dataset on JANX007 sends the group’s stock down.

But the group still hopes to get IGV-001 approved based on overall survival data.

The agency approved eight oncology products over the month.